GO:0019807 aspartoacylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019807 aspartoacylase activity is a molecular_function defined as catalysis of the reaction N-acyl-L-aspartate + H2O = a fatty acid anion + L-aspartate.
• The canonical enzyme is ASPA (aspartoacylase, also called aminoacylase II), which hydrolyzes N-acetylaspartate (NAA) into aspartate and acetate.
• In the central nervous system, aspartoacylase activity is enriched in oligodendrocytes and is responsive to glutamatergic activity.
• Loss-of-function ASPA mutations cause Canavan disease, and residual enzyme activity correlates with clinically distinct phenotypes.
• Beyond leukodystrophy, aspartoacylase has been implicated in fibroblast biology and cancer progression, including prostate cancer suppression via LYN blockade.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of aspartoacylase activity in disease and cell biology.
Description
Aspartoacylase activity (GO:0019807) is a molecular_function that catalyzes the hydrolysis of N-acyl-L-aspartate substrates into a fatty acid anion and L-aspartate. The best-characterized reaction is the deacetylation of N-acetylaspartate (NAA) to aspartate and acetate, a step central to NAA catabolism in the brain. Because NAA is one of the most abundant amino acid derivatives in the mammalian central nervous system, its turnover by aspartoacylase is a key node in neurochemistry and myelin biology. Researchers study aspartoacylase activity because its dysfunction is directly linked to Canavan disease, a severe leukodystrophy caused by biallelic ASPA mutations. The enzyme is also emerging as a modifier of signaling pathways outside the brain, including TGF-beta responses in fibroblasts and LYN-dependent pathways in prostate cancer. This makes GO:0019807 relevant to neurobiology, cancer biology, and metabolic disease research. This article summarizes the QuickGO definition, the catalytic and cellular context of aspartoacylase activity, the genes and proteins involved, disease associations, and the experimental methods used to interrogate this function.
aspartoacylase activity At A Glance
| GO ID | GO:0019807 |
|---|---|
| GO term | aspartoacylase activity |
| Ontology | molecular_function |
| Definition | Catalysis of the reaction: N-acyl-L-aspartate + H2O = a fatty acid anion + L-aspartate |
| Synonym | acetyl-aspartic deaminase activity; acylase II; aminoacylase II activity; N-acetylaspartate amidohydrolase activity; N-acyl-L-aspartate amidohydrolase activity |
| Major function | Hydrolytic deacylation of N-acyl-L-aspartate substrates, including N-acetylaspartate |
| Canonical enzyme | ASPA (aspartoacylase) |
| Primary tissue context | Central nervous system, particularly oligodendrocytes |
| Disease link | Canavan disease; emerging roles in cancer biology |
What Is GO:0019807?
In the QuickGO ontology, aspartoacylase activity (GO:0019807) is defined as catalysis of the reaction N-acyl-L-aspartate + H2O = a fatty acid anion + L-aspartate. It is a molecular_function term with synonyms including acetyl-aspartic deaminase activity, acylase II, aminoacylase II activity, N-acetylaspartate amidohydrolase activity, and N-acyl-L-aspartate amidohydrolase activity. In practice, the term describes the enzymatic removal of an acyl group from an N-acyl-L-aspartate, most commonly the conversion of N-acetylaspartate to aspartate and acetate.
Why Is aspartoacylase activity Important in Cell Biology?
Aspartoacylase activity is important because it controls the catabolism of N-acetylaspartate, a highly abundant brain metabolite, and its loss causes Canavan disease, a devastating leukodystrophy. The enzyme is also expressed in macroglial cells and is regulated by glutamatergic activity, linking it to neuronal-glial communication. More recently, aspartoacylase has been implicated in fibroblast TGF-beta signaling and prostate cancer progression, indicating broader roles beyond the nervous system.
• Defines the enzymatic step that converts N-acetylaspartate to aspartate and acetate in the brain.
• Loss-of-function mutations in ASPA cause Canavan disease, a severe inherited leukodystrophy.
• Residual aspartoacylase enzyme activity correlates with clinically distinct Canavan disease phenotypes.
• Expression is enriched in oligodendrocytes among macroglial cells, linking the enzyme to myelin biology.
• Endogenous aspartoacylase expression responds to glutamatergic activity in vitro and in vivo.
• Mutational analysis of aspartoacylase provides structure-function insight relevant to disease variants.
• Restoring aspartoacylase activity in CNS neurons alone does not ameliorate motor deficits and demyelination in a Canavan disease model, highlighting cell-type-specific requirements.
• Aspartoacylase suppresses TGF-beta-mediated responses and cancer progression in fibroblasts.
• Aspartoacylase suppresses prostate cancer progression by blocking LYN activation.
• Provides a tractable target for CRISPR knockout, point-mutation, and knock-in studies in metabolic and cancer research.
Molecular Mechanism of aspartoacylase activity
Substrate recognition and binding
In simple terms: The enzyme grabs a specific modified amino acid called N-acetylaspartate and holds it in place.
Aspartoacylase activity acts on N-acyl-L-aspartate substrates, with N-acetylaspartate (NAA) being the principal physiological substrate. The enzyme is also known as N-acetylaspartate amidohydrolase, reflecting its specificity for the amide bond between the acetyl group and aspartate. Mutational analysis of aspartoacylase has identified residues critical for substrate binding and catalysis, providing a structural basis for understanding disease-causing variants.
Hydrolytic cleavage of the acyl group
In simple terms: Water is used to cut the acetyl group off, releasing aspartate and acetate.
The catalytic reaction follows the general scheme N-acyl-L-aspartate + H2O = a fatty acid anion + L-aspartate. In the case of NAA, hydrolysis yields aspartate and acetate. This amidohydrolase activity is the defining biochemical function of the ASPA enzyme and is measured experimentally as aspartoacylase enzyme activity.
Cell-type expression and regulation
In simple terms: The enzyme is mainly found in a specific brain cell type and its levels change with brain activity.
Among cultured rat macroglial cells, expression of aspartoacylase activity is limited to oligodendrocytes. Endogenous aspartoacylase expression is responsive to glutamatergic activity both in vitro and in vivo, suggesting that neuronal signals regulate the enzyme. This cell-type specificity and activity-dependent regulation position aspartoacylase at the interface of neuronal and glial metabolism.
Functional consequences of loss or restoration
In simple terms: When the enzyme is missing, brain problems occur; putting it back in the wrong cells may not fix them.
Loss of aspartoacylase activity leads to Canavan disease, and residual enzyme activity correlates with distinct clinical phenotypes. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease, indicating that neuronal expression alone is insufficient for rescue. These findings underscore the importance of cell-type-specific expression for the physiological function of aspartoacylase activity.
Non-canonical roles in signaling and cancer
In simple terms: The enzyme also appears to influence cell signaling and cancer growth outside the brain.
Fibroblastic aspartoacylase suppresses TGF-beta-mediated responses and cancer progression. In prostate cancer, aspartoacylase suppresses progression by blocking LYN activation. These studies expand the functional scope of aspartoacylase activity beyond NAA catabolism into signaling regulation and tumor suppression.
Key Genes Involved in GO:0019807 aspartoacylase activity
The genes and proteins below are directly implicated in aspartoacylase activity (GO:0019807) or its physiological and pathological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ASPA | Encodes aspartoacylase, the enzyme catalyzing N-acetylaspartate hydrolysis | Canonical gene for GO:0019807; mutations cause Canavan disease |
| NAT8L | Synthesizes N-acetylaspartate, the substrate of aspartoacylase | Provides substrate for aspartoacylase activity; relevant to NAA metabolism |
| LYN | Src-family kinase blocked by aspartoacylase in prostate cancer | Links aspartoacylase activity to cancer signaling |
| TGFB1 | TGF-beta ligand whose responses are suppressed by fibroblastic aspartoacylase | Connects aspartoacylase to TGF-beta signaling and cancer progression |
| ASPA variants | Disease-associated mutations altering enzyme activity | Used in mutational analysis and genotype-phenotype studies |
| Oligodendrocyte markers (e.g., MBP) | Mark the cell type expressing aspartoacylase activity in macroglia | Context for cell-type-specific expression studies |
| Glutamate receptors | Mediate glutamatergic regulation of aspartoacylase expression | Link neuronal activity to aspartoacylase regulation |
| ASPA (neuronal expression) | Ectopic expression in CNS neurons in Canavan models | Tests whether neuronal restoration rescues disease |
| ASPA (fibroblast expression) | Suppresses TGF-beta responses in fibroblasts | Non-CNS role in cancer progression |
| ASPA (prostate cancer cells) | Suppresses prostate cancer progression via LYN blockade | Cancer relevance of aspartoacylase activity |
| ASPA (oligodendrocytes) | Primary site of aspartoacylase activity in macroglia | Cell-type-specific function in myelin biology |
| ASPA (astrocytes) | Lack aspartoacylase activity in culture | Negative control for cell-type specificity |
| ASPA (microglia) | Lack aspartoacylase activity in culture | Negative control for cell-type specificity |
| ASPA (Canavan disease alleles) | Residual activity correlates with phenotype | Genotype-phenotype correlation studies |
| ASPA (Arab populations) | Founder mutations in Canavan disease | Population genetics and diagnostics |
| ASPA (mutant constructs) | Structure-function analysis of catalytic residues | Mutational analysis for disease variants |
| ASPA (CNS neurons) | Restoration does not rescue motor deficits | Cell-type-specific therapeutic testing |
| ASPA (fibroblasts) | Suppresses TGF-beta-mediated responses | Fibroblast biology and cancer progression |
How Is aspartoacylase activity Regulated?
Aspartoacylase activity is regulated at the level of enzyme expression and cell-type specificity. Endogenous aspartoacylase expression is responsive to glutamatergic activity in vitro and in vivo, indicating activity-dependent regulation. Among macroglial cells, expression of aspartoacylase activity is limited to oligodendrocytes, suggesting cell-type-specific transcriptional control. Disease-associated mutations in ASPA reduce residual enzyme activity, and this residual activity correlates with clinical phenotype severity. In cancer contexts, aspartoacylase expression suppresses TGF-beta-mediated responses and LYN activation, implying that its levels or activity influence signaling pathways.
aspartoacylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ASPA | Canavan disease / leukodystrophy | ASPA knockout or point-mutation knock-in in oligodendrocyte lineage cells |
| ASPA | Prostate cancer progression | ASPA overexpression in prostate cancer cell lines |
| ASPA | TGF-beta signaling in fibroblasts | ASPA knockout or overexpression in fibroblasts |
| ASPA | N-acetylaspartate metabolism | ASPA knockout in neuronal or glial cultures |
| ASPA | Population-specific founder mutations | Patient-derived cells with ASPA mutations |
Canavan disease and leukodystrophy
Canavan disease is a severe inherited leukodystrophy caused by loss of aspartoacylase activity due to ASPA mutations. Clinically distinct phenotypes correlate with residual aspartoacylase enzyme activity, making enzyme activity a key biomarker and genotype-phenotype readout. Mutational analysis of aspartoacylase has provided insight into how disease-causing variants impair catalysis. In a model of Canavan disease, restoration of aspartoacylase activity in CNS neurons did not ameliorate motor deficits and demyelination, highlighting the importance of appropriate cell-type targeting.
Cancer progression and signaling
Fibroblastic aspartoacylase suppresses TGF-beta-mediated responses and cancer progression, indicating a tumor-suppressive role outside the nervous system. In prostate cancer, aspartoacylase suppresses progression by blocking LYN activation. These findings link GO:0019807 to cancer cell signaling and suggest that aspartoacylase activity may modulate oncogenic pathways.
Neuro-glial metabolism and glutamatergic signaling
Aspartoacylase activity is enriched in oligodendrocytes among macroglial cells and is responsive to glutamatergic activity. This positions the enzyme within neuro-glial metabolic coupling and suggests that perturbations in glutamatergic signaling could alter NAA catabolism.
From aspartoacylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of aspartoacylase activity cause metabolic or myelin defects? | ASPA knockout cell model (e.g., oligodendrocyte lineage) |
| How do disease-associated ASPA mutations affect enzyme activity? | Point-mutation knock-in of specific ASPA variants |
| Can restoring aspartoacylase activity rescue disease phenotypes? | Knock-in or overexpression of ASPA in CNS neurons or oligodendrocytes |
| What is the subcellular localization of aspartoacylase? | Tagged knock-in of ASPA with fluorescent or affinity tags |
| Does aspartoacylase suppress cancer progression? | ASPA overexpression in prostate cancer or fibroblast models |
| How does glutamatergic activity regulate aspartoacylase expression? | ASPA reporter or tagged knock-in in neurons and glia |
How to Study the aspartoacylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Hydrolysis of N-acetylaspartate to aspartate and acetate | Quantifying residual aspartoacylase activity in mutants |
| Western blot | ASPA protein expression levels | Comparing expression across cell types |
| Immunostaining | Cell-type localization of aspartoacylase | Identifying oligodendrocyte-specific expression |
| Glutamatergic stimulation assays | Activity-dependent changes in aspartoacylase expression | Testing neuronal regulation |
| Mutagenesis and transfection | Effect of ASPA variants on enzyme function | Structure-function analysis |
| CRISPR knockout | Loss-of-function phenotypes | Testing causal roles in disease models |
| Overexpression | Gain-of-function effects | Cancer and signaling studies |
| Genotype-phenotype correlation | Residual activity vs clinical severity | Canavan disease variant classification |
Enzyme activity assays
Aspartoacylase enzyme activity is measured biochemically by monitoring the hydrolysis of N-acetylaspartate to aspartate and acetate. Residual enzyme activity in patient samples or mutant constructs is a key readout for genotype-phenotype correlations in Canavan disease. Mutational analysis of aspartoacylase uses such assays to determine the impact of specific amino acid substitutions on catalysis.
Cell-type-specific expression analysis
Expression of aspartoacylase activity among macroglial cells is limited to oligodendrocytes, which can be demonstrated by comparing enzyme activity or expression across cultured astrocytes, microglia, and oligodendrocytes. Endogenous aspartoacylase expression is responsive to glutamatergic activity, which can be studied using in vitro neuronal-glial co-cultures and in vivo models.
Genetic and mutational models
Mutational analysis of aspartoacylase involves introducing disease-associated variants and measuring their effect on enzyme function. Restoration of aspartoacylase activity in CNS neurons in a Canavan disease model tests whether cell-type-specific expression can rescue motor deficits and demyelination. Population-specific founder mutations can be modeled using patient-derived cells or CRISPR-edited lines.
Cancer and signaling assays
In cancer biology, aspartoacylase function is studied by overexpressing or knocking out ASPA in prostate cancer cells and fibroblasts, followed by assays for proliferation, TGF-beta responses, and LYN activation. These approaches link GO:0019807 to signaling pathways and tumor progression.
How CRISPR Can Be Used to Study GO:0019807 aspartoacylase activity
Knockout
CRISPR knockout of ASPA can eliminate aspartoacylase activity in cell models to study metabolic consequences, myelin biology, and disease phenotypes. Knockout in oligodendrocyte lineage cells is particularly relevant because aspartoacylase activity is enriched in oligodendrocytes among macroglial cells.
Point Mutation
Point-mutation knock-in of disease-associated ASPA variants allows precise testing of how specific amino acid changes affect enzyme activity and clinical phenotype correlations. Such models are valuable for dissecting structure-function relationships in aspartoacylase.
Knock-in
Tagged or reporter knock-in of ASPA enables visualization of endogenous expression and subcellular localization in relevant cell types. Knock-in of wild-type ASPA in disease models can test whether restoring activity in specific cell types rescues phenotypes.
Overexpression
Overexpression of ASPA is used to study gain-of-function effects, including suppression of TGF-beta responses in fibroblasts and inhibition of prostate cancer progression via LYN blockade. These models help define the broader signaling roles of aspartoacylase activity.
How EDITGENE Supports aspartoacylase activity Research
Researchers studying aspartoacylase activity-related genes often need to determine whether a candidate gene is causally involved in N-acetylaspartate metabolism, leukodystrophy, or cancer signaling. EDITGENE provides CRISPR-based cell model services to enable such causal experiments.
Contact EDITGENE today to design your custom CRISPR model for aspartoacylase activity research.
Frequently Asked Questions About aspartoacylase activity
What is aspartoacylase activity?
Aspartoacylase activity (GO:0019807) is a molecular_function defined as catalysis of the reaction N-acyl-L-aspartate + H2O = a fatty acid anion + L-aspartate.
What gene encodes aspartoacylase?
The ASPA gene encodes aspartoacylase, the enzyme responsible for GO:0019807.
What does aspartoacylase do in the brain?
It hydrolyzes N-acetylaspartate to aspartate and acetate, and its activity is enriched in oligodendrocytes among macroglial cells.
What diseases are linked to aspartoacylase activity?
Loss of aspartoacylase activity causes Canavan disease, and residual activity correlates with clinical phenotype.
Is aspartoacylase activity involved in cancer?
Yes, fibroblastic aspartoacylase suppresses TGF-beta-mediated responses and cancer progression, and it suppresses prostate cancer progression by blocking LYN activation.
How is aspartoacylase activity regulated?
Endogenous aspartoacylase expression is responsive to glutamatergic activity, and expression is cell-type-specific.
What are synonyms for aspartoacylase activity?
Synonyms include acetyl-aspartic deaminase activity, acylase II, aminoacylase II activity, N-acetylaspartate amidohydrolase activity, and N-acyl-L-aspartate amidohydrolase activity.
Can restoring aspartoacylase activity in neurons rescue Canavan disease?
Restoration of aspartoacylase activity in CNS neurons did not ameliorate motor deficits and demyelination in a model of Canavan disease.
What experimental models are used to study aspartoacylase activity?
Models include ASPA knockout, point-mutation knock-in, tagged knock-in, and overexpression cell lines, as well as enzyme activity assays.
What is the GO ID for aspartoacylase activity?
The GO ID is GO:0019807.
Conclusion
Aspartoacylase activity (GO:0019807) is a well-defined molecular_function with a central role in N-acetylaspartate catabolism and profound links to Canavan disease. Its cell-type-specific expression in oligodendrocytes and regulation by glutamatergic activity highlight its importance in neuro-glial biology. Emerging evidence for roles in TGF-beta signaling and prostate cancer progression broadens the relevance of aspartoacylase activity beyond the nervous system. CRISPR-based cell models provide powerful tools to dissect these functions causally.
References
- 1. Astobiza I et al.. 2026. Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression.. Nat Commun 17(1) PMID: 42303618
- 2. Baslow MH et al.. 1999. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes.. J Mol Neurosci 13(1-2):47-53 PMID: 10691291
- 3. Francis JS et al.. 2011. Endogenous aspartoacylase expression is responsive to glutamatergic activity in vitro and in vivo.. Glia 59(10):1435-46 PMID: 21608034
- 4. Hershfield JR et al.. 2007. Mutational analysis of aspartoacylase: implications for Canavan disease.. Brain Res 1148:1-14 PMID: 17391648
- 5. Mendes MI et al.. 2017. Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.. Hum Mutat 38(5):524-531 PMID: 28101991
- 6. Weng H et al.. 2023. Aspartoacylase suppresses prostate cancer progression by blocking LYN activation.. Mil Med Res 10(1):25 PMID: 37271807
- 7. Klugmann M et al.. 2005. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.. Mol Ther 11(5):745-53 PMID: 15851013
- 8. Zayed H. 2015. Canavan disease: an Arab scenario.. Gene 560(1):9-14 PMID: 25668701
